Volpara Solutions Limited is the wholly-owned sales and marketing arm of Volpara Health Technologies Limited a research, development and manufacturing company that develops digital health solutions to enable personalized, high-quality breast cancer screening. Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Volpara Health Technologies Limited is based in Wellington, New Zealand.
With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, it applies science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO27001 and ISO13485, and is a US FDA–registered establishment whose products are listed accordingly. In addition, their products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara solutions products are VolparaEnterprise, VolparaEnterprise DDP, VolparaDensity, and Volpara data manager.
VolparaEnterprise software enables breast imaging providers to perform rapid quality control checks to optimize the productivity and efficiency of imaging resources, help reduce costs through the reduction of retakes, increase staff effectiveness, and provide objective evidence to demonstrate compliance and quality of care.
VolparaEnterprise Clinical Applications provide quick, automated assessment of every exam, producing a Volpara Scorecard that includes VolparaDensity, VolparaDose, and VolparaPressure. VolparaDensity provides fast, objective assessment of a woman’s breast density from a mammogram from most x-ray vendors. It produces a patient scorecard within two minutes of the last x-ray, enabling a discussion with the woman about her breast density while she is still in the center and, if necessary, additional imaging.